Publications: Aung-Htut, May
Journal Article
Aung-Htut, M.T., Ham, K.A.
ORCID: 0000-0002-7036-5334, Tchan, M.C., Fletcher, S. and Wilton, S.D.
(2020)
Novel mutations found in individuals with adult-onset Pompe disease.
Genes, 11
(2).
Article 135.
Aung-Htut, M.T., Ham, K.A.ORCID: 0000-0002-7036-5334, Tchan, M., Johnsen, R., Schnell, F.J., Fletcher, S. and Wilton, S.D.
(2020)
Splice modulating antisense oligonucleotides restore some acid-alpha-glucosidase activity in cells derived from patients with late-onset Pompe disease.
Scientific Reports, 10
.
Article number: 6702.
Zaw, K., Greer, K., Aung-Htut, M.T., Mitrpant, C., Veedu, R.N., Fletcher, S. and Wilton, S.D. (2019) Consequences of making the inactive active through changes in antisense oligonucleotide chemistries. Frontiers in Genetics, 10 .
Aung-Htut, M.T., McIntosh, C.S., West, K.A.ORCID: 0000-0002-7036-5334, Fletcher, S. and Wilton, S.D.
(2019)
In vitro validation of phosphorodiamidate morpholino oligomers.
Molecules, 24
(16).
Article 2922.
Aung-Htut, M.T., Comerford, I., Johnsen, R., Foyle, K., Fletcher, S. and Wilton, S.D. (2019) Reduction of integrin alpha 4 activity through splice modulating antisense oligonucleotides. Scientific Reports, 9 (1).
McIntosh, C.S., Aung-Htut, M.T., Fletcher, S. and Wilton, S.D. (2019) Removal of the polyglutamine repeat of ataxin-3 by redirecting pre-mRNA processing. International Journal of Molecular Sciences, 20 (21). Article 5434.
Aung-Htut, M.T., McIntosh, C.S., Ham, K.A.ORCID: 0000-0002-7036-5334, Pitout, I.L., Flynn, L.L., Greer, K., Fletcher, S. and Wilton, S.D.
(2019)
Systematic approach to developing splice modulating antisense oligonucleotides.
International Journal of Molecular Sciences, 20
(20).
Article 5030.
Aung-Htut, M.T., West, K., Barrett, L., Cardwell, K., Schnell, F.J., Fletcher, S. and Wilton, S.D. (2018) Late onset Pompe disease: Rescue of acid alpha-glucosidase expression by splice modification. Journal of Gene Medicine, 20 (1).
McIntosh, C.S., Aung-Htut, M.T., Fletcher, S. and Wilton, S.D. (2018) The use of antisense oligonucleotide-mediated exon skipping to treat spinocerebellar ataxia type 3. Journal of Gene Medicine, 20 (1).
Chakravarthy, M., Aung-Htut, M.T., Le, B.T. and Veedu, R.N. (2017) Novel Chemically-modified DNAzyme targeting Integrin alpha-4 RNA transcript as a potential molecule to reduce inflammation in multiple sclerosis. Scientific Reports, 7 (1).
Fraidenraich, D., Toh, Z.Y.C., Aung-Htut, M.T., Pinniger, G., Adams, A.M., Krishnaswarmy, S., Wong, B.L., Fletcher, S. and Wilton, S.D. (2016) Deletion of dystrophin In-Frame Exon 5 leads to a severe phenotype: Guidance for Exon skipping strategies. PloS one, 11 (1). e0145620.